Companies › EyeD Pharma
1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Timolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Glaucoma | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07036510 | Timolol | Phase 1 | Glaucoma | Ophthalmology | Jan 2027 |
Chiesi Farmaceutici AstraZeneca Actimed Therapeutics ARS Pharmaceuticals Acer Therapeutics GSK Tecnoquimicas Lunan Better Pharmaceutical Polarean Novartis
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.